Results 1 to 10 of about 23,803 (118)

Inhibition of Glucose-Induced Glycation of HSA by Pioglitazone: Multi-Spectroscopic and Bioinformatic Evidence [PDF]

Molecules
Diabetes mellitus is a growing health concern that causes numerous complications. Glycation produces advanced glycation end-products (AGEs), which promote diabetic complications. Targeting glycation is a strategy for combating the progression of diabetic
Jihad Alrehaili, Razique Anwer
doaj   +2 more sources

The efficacy of pioglitazone for renal protection in diabetic kidney disease

PLoS ONE, 2022
There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients.
Chao-Chung Ho, Yi-Sun Yang, Chien-Ning Huang, Shih-Chang Lo, Yu-Hsun Wang, Edy Kornelius   +5 more
doaj   +2 more sources

Implications of Pharmacokinetic Potentials of Pioglitazone Enantiomers in Rat Plasma Mediated through Glucose Uptake Assay

Molecules, 2023
Pioglitazone, a PPAR-gamma activator used to diagnose hyperglycemia, was studied for its stereoselective deposition and active enantiomers in female albino Wistar rats.
Tatineni Spandana, Veera Venkata Nishanth Goli, Mohamed Rahamathulla, Sirajunisa Talath, Riyaz Ali M. Osmani, Mohammed Muqtader Ahmed, Syeda Ayesha Farhana, Shalam Mohamed Hussain, Bannimath Gurupadayya   +8 more
doaj   +1 more source

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

Hepatology Communications, 2021
The antidiabetic drug pioglitazone is, to date, the most efficacious oral drug recommended off‐label for the treatment of nondiabetic or diabetic patients with biopsy‐proven nonalcoholic steatohepatitis (NASH). However, weight gain and edema side effects
Vincent Jacques, Sébastien Bolze, Sophie Hallakou‐Bozec, Anthony W. Czarnik, Ajit S. Divakaruni, Pascale Fouqueray, Anne N. Murphy, Lex H.T. Van der Ploeg, Sheila DeWitt   +8 more
doaj   +1 more source

Pioglitazone - the forgotten drug with multidirectional action

Journal of Education, Health and Sport, 2023
Introduction: Pioglitazone (PG) which belongs to thiazolidinedione class is a drug used in the treatment of type 2 diabetes. PG increases the insulin sensitivity of peripheral tissues.
Arkadiusz Aab, Julia Zarańska
doaj   +1 more source

Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects [PDF]

International Neurourology Journal, 2020
Purpose Pioglitazone, an antihyperglycemic drug, is widely used in diabetes mellitus patients with insulin resistance. Although pioglitazone is known to have a potential link to bladder cancer (BC), there have been contradictory results.
Muhammad Shahid, Minhyung Kim, Austin Yeon, Peng Jin, Woong-Ki Kim, Sungyong You, Jayoung Kim   +6 more
doaj   +1 more source

Pioglitazone abrogates testicular damage induced by testicular torsion/detorsion in rats [PDF]

Iranian Journal of Basic Medical Sciences, 2019
Objective(s): Testicular torsion/detorsion (T/D) is a well-known cause for infertility. Pioglitazone is an agonist of peroxisome proliferator activated receptor-gamma (PPAR-γ).
Nevertyty Mohamed Mahmoud, Soad Lotfy Kabil   +1 more
doaj   +1 more source

Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication

Drugs - Real World Outcomes, 2019
Introduction A Direct Healthcare Professional Communication (DHPC) sent in Denmark on 11 August 2011 provided information on new pioglitazone labelling and guidance on monitoring treatment effectiveness.
Javier Cid Ruzafa, Sinna Pilgaard Ulrichsen, Dimitri Bennett, Vera Ehrenstein   +3 more
doaj   +1 more source

Fish oil prevents excessive accumulation of subcutaneous fat caused by an adverse effect of pioglitazone treatment and positively changes adipocytes in KK mice

Toxicology Reports, 2016
Pioglitazone, a thiazolidinedione (TZD), is widely used as an insulin sensitizer in the treatment of type 2 diabetes. However, body weight gain is frequently observed in TZD-treated patients. Fish oil improves lipid metabolism dysfunction and obesity. In
Yuzuru Iizuka, Hyounju Kim, Maki Nakasatomi, Takuya Izawa, Satoshi Hirako, Akiyo Matsumoto   +5 more
doaj   +1 more source

Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial

National Journal of Physiology, Pharmacy and Pharmacology, 2023
Background: On 18th June 2013, India banned pioglitazone, a peroxisome proliferation activator gamma agonist, and a popular anti-diabetic drug used in the treatment of type 2 diabetes mellitus (T2DM), but on 21st August 2013, ban was revoked after stiff ...
Allen Joe Rodrigues, Laxminarayana Kamath, Shreya Chokshi, Raveendra K R   +3 more
doaj   +1 more source